Ventyx Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ventyx Biosciences, Inc. - overview
Established
2019
Location
-, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2019 by founder Raju Mohan, Ventyx Biosciences, Inc. operates as a clinical-stage biotechnology company. In March 2024, Ventyx Biosciences, Inc. raised USD 100 million in PIPE funding led by investor Farallon Capital Management, with participation from other investors Cormorant Asset Management, Redmile Group, and Surveyor Capital.
As part of the transaction, the company agreed to sell 11. 17 million shares of common stock in a private placement for USD 100 million at USD 8. 95 per share. The company got listed on the Nasdaq Global Select Market under the ticker symbol VTY.
Ventyx Biosciences, Inc. is a developer of immunology drugs that offers programs such as SP1P1R, TYK2, NLRPR, cGAS, Gasdermin D. The company's clinical stage pipeline includes: VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of autoimmune diseases; VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis; and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company will use the March 2024 funding for advancing clinical and preclinical program developments, expanding research activities, and supporting general corporate operations.
Current Investors
Sanofi, OrbiMed Advisors, Vivo Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.ventyxbio.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Ventyx Biosciences, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Ventyx Biosciences, Inc. | - | ||||||||
| PIPE | Completed | Ventyx Biosciences, Inc. | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.